PHARMENA SA is a dynamically-developing, public limited biotechnology company. Our main line of business is development and commercialization of innovative products based on a patented physiological and natural active ingredient – 1‑MNA.
The Company’s business concentrates on clinical trials of this innovative anti-inflammatory and anti-fibrotic drug and implementation on the market innovative dietary supplements used to satisfy special dietary needs.
The discovery of 1-MNA is the result of many years of research at various research sites all over the world. Scientists from Poland, the United States, Germany, Switzerland, Spain, Sweden, Denmark, Japan, China and Iran have conducted hundreds of studies on the 1-MNA molecule.
1-MNA is a substance that occurs naturally in the human body. It is formed as a result of the metabolism of niacin. Niacin takes part in the synthesis of the coenzymes NAD+ and NADP+, which are found in numerous cells and are involved in a range of important processes in the body. As we age, our body’s ability to convert niacin to 1-MNA decreases and the amount of coenzyme NAD+ drops as well. This process starts after the age of 30. It has been confirmed that between the ages 40 and 60, NAD+ levels go down by up to 50%. This results in slower cell production and ageing. In young cells and tissues, NAD+ levels are higher, which translates into good physical activity and cognitive function as well as greater potential for cell regeneration.
1-MNA, which optimizes NAD+ levels, constitutes a new approach to this process. The molecule is patented (EP 1713480).
